HI — Hillenbrand, Inc.

Hillenbrand Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $599 million, down 24% year-over-year (10% on a pro forma basis), primarily due to the divestiture of the Milacron Injection Molding & Extrusion (MIME) business and lower capital equipment volume in the Advanced Process Solutions (APS) segment.
• Adjusted EBITDA: $84 million, a decrease of 28% year-over-year, with a margin of 14.1%, down 360 basis points due to lower volumes and unfavorable product mix.
• Net Income: $2 million, a recovery from a loss of $249 million in the prior year, attributed to a noncash impairment charge in 2024.
• Adjusted EPS: $0.51, a 40% decrease compared to the prior year, in line with expectations.
• Cash Flow: A use of approximately $2 million in operations due to lower customer advances; capital expenditures were $10 million.
• Net Debt: $1.51 billion, with a net debt to pro forma adjusted EBITDA ratio of 3.9x, improved to 3.7x post-divestiture of TerraSource.

2. Strategic Updates and Business Highlights

• Portfolio Simplification: Successfully divested MIME, generating $265 million in net proceeds, and sold a minority interest in TerraSource for $115 million, significantly reducing debt.
• Cost Synergies: Achieved $30 million in run rate cost synergies from Linxis and FPM acquisitions, ahead of the original timeline.
• Market Positioning: Focused on higher-margin, higher-growth businesses in Performance Materials and Food, Health and Nutrition (FHN) sectors. FHN now represents over 25% of global revenue.
• Integration Efforts: Continued integration of FHN businesses and ramping up cross-selling initiatives leveraging Coperion’s global footprint.

3. Forward Guidance and Outlook

• Revenue Guidance: Updated range for fiscal year 2025 raised to $2.59 billion - $2.63 billion.
• Adjusted EPS Guidance: Narrowed to $2.20 - $2.35, maintaining the midpoint of previous guidance.
• Operating Cash Flow: Expected to be approximately $60 million with $40 million in capital expenditures, prioritizing in-region, for-region projects.
• Market Activity: Recent uptick in orders post-quarter end provides optimism for Q4 and beyond.

4. Challenges and Points of Concern

• Order Delays: Continued cautious order behavior due to global macroeconomic uncertainty and tariff announcements, leading to delays in project decisions rather than cancellations.
• Declining Metrics: Year-over-year declines in revenue and adjusted EBITDA reflect ongoing challenges in the APS segment, with capital orders down due to tariff uncertainties.
• Competitive Pressures: Pricing remains challenging in the Molding Technology Solutions (MTS) segment, with a competitive environment persisting due to low volumes.

5. Notable Q&A Insights

• Order Activity: Post-quarter, there has been a positive uptick in orders, particularly in the plastics sector, with strong quoting and test facility activity.
• Backlog Trends: While backlog in APS has decreased, there is confidence that recent order trends will support recovery and growth moving into the next fiscal year.
• Cash Flow Considerations: Future cash flow is expected to improve with incoming orders, and the company is focused on debt reduction as a priority.
• Dividend Discussion: The Board regularly reviews dividend policies, but no immediate changes were announced regarding dividends amidst current leverage concerns.

This summary encapsulates Hillenbrand's financial performance, strategic initiatives, outlook, challenges, and insights from the earnings call, providing a comprehensive overview for stakeholders.